Über uns
Über uns
Führungsteam
Unsere Verantwortung
Kollaborationen
Unsere Standorte
Technologie
Technologie
Produktion
Publikationen
Pipeline
Newsroom
News
Events
Downloads
Investor Relations
Überblick
Analysten-Coverage
Hauptversammlung
Finanzberichte
Corporate Governance
E-Mail Alert
Karriere
Werden Sie Teil der RNA people
Ausbildung
Aktuelle Stellenangebote
DE
Oncology
Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors
by Sovereign
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
by Sovereign
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
by Sovereign
Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
by Sovereign
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
by Sovereign
Immunological effects of a novel RNA-based adjuvant in liver cancer patients
by Sovereign
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
by Sovereign
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
by Sovereign
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
by Sovereign
mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
by Sovereign
1
2